WO2012075484A9 - Novel drug targets to overcome de novo drug-resistance in multiple myeloma - Google Patents

Novel drug targets to overcome de novo drug-resistance in multiple myeloma Download PDF

Info

Publication number
WO2012075484A9
WO2012075484A9 PCT/US2011/063266 US2011063266W WO2012075484A9 WO 2012075484 A9 WO2012075484 A9 WO 2012075484A9 US 2011063266 W US2011063266 W US 2011063266W WO 2012075484 A9 WO2012075484 A9 WO 2012075484A9
Authority
WO
WIPO (PCT)
Prior art keywords
drug
overcome
resistance
multiple myeloma
novo
Prior art date
Application number
PCT/US2011/063266
Other languages
French (fr)
Other versions
WO2012075484A2 (en
Inventor
Daniel M. Sullivan
Thomas C. Rowe
David A. Ostrov
Joel G. Turner
Original Assignee
H. Lee Moffitt Cancer Center And Research Institute, Inc.
University Of Florida Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lee Moffitt Cancer Center And Research Institute, Inc., University Of Florida Research Foundation, Inc. filed Critical H. Lee Moffitt Cancer Center And Research Institute, Inc.
Publication of WO2012075484A2 publication Critical patent/WO2012075484A2/en
Publication of WO2012075484A9 publication Critical patent/WO2012075484A9/en
Priority to US13/908,339 priority Critical patent/US9616051B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2011/063266 2008-12-12 2011-12-05 Novel drug targets to overcome de novo drug-resistance in multiple myeloma WO2012075484A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/908,339 US9616051B2 (en) 2008-12-12 2013-06-03 Drug targets to overcome de novo drug-resistance in multiple myeloma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41953610P 2010-12-03 2010-12-03
US61/419,536 2010-12-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/159,016 Continuation US8623854B2 (en) 2008-12-12 2011-06-13 Nuclear export inhibitors of topoisomerase II alpha

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/908,339 Continuation US9616051B2 (en) 2008-12-12 2013-06-03 Drug targets to overcome de novo drug-resistance in multiple myeloma

Publications (2)

Publication Number Publication Date
WO2012075484A2 WO2012075484A2 (en) 2012-06-07
WO2012075484A9 true WO2012075484A9 (en) 2012-08-09

Family

ID=46172608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063266 WO2012075484A2 (en) 2008-12-12 2011-12-05 Novel drug targets to overcome de novo drug-resistance in multiple myeloma

Country Status (1)

Country Link
WO (1) WO2012075484A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511214B (en) * 2019-06-28 2021-07-27 浙江工业大学 Diamine substituted aromatic heterocyclic compound and preparation method and application thereof

Also Published As

Publication number Publication date
WO2012075484A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
AU2016202472A1 (en) Stable formulations of a hyaluronan-degrading enzyme
EP2581249B8 (en) Tractor with different energy sources
EP2706987B8 (en) Pharmaceutical compositions
EP2756475A4 (en) Distributing multi-source push notifications to multiple targets
EP3144319B8 (en) Cell culture composition comprising laminin-521
EP2620668A4 (en) Front fork
EP2547331A4 (en) Gastro-resistant enzyme pharmaceutical compositions
AU2012252633A1 (en) Drawer
AU2016202513A1 (en) Composition
EP2609209A4 (en) Compound selection in drug discovery
EP2736903B8 (en) Aryl naphthalide lignans as anti-hiv agents
EP2697183B8 (en) Composter
EP2588224A4 (en) Variable-orifice prill plate
AU2011100432A4 (en) Innovative Precision Agriculture Software
WO2012075484A9 (en) Novel drug targets to overcome de novo drug-resistance in multiple myeloma
AU2011100382A4 (en) Now Reminder
AU2013204095B2 (en) Pharmaceutical composition
AU2013204097B2 (en) Pharmaceutical composition
AU2011901358A0 (en) Composter
AU2011905393A0 (en) Pharmaceutical Composition
AU2011902280A0 (en) Biomass
AU2011902255A0 (en) Direct Compost Solutions
AU2011904720A0 (en) Hoe improvements
AU2011900181A0 (en) Bioreactor
AU2010900203A0 (en) Bioreactor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11844052

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11844052

Country of ref document: EP

Kind code of ref document: A2